Background: Although airway hyperresponsiveness to inhaled acetaldehyde has been documented in Japanese patients with asthma, the response to this bronchoconstrictor agent has never been studied in Caucasians.
Objectives: The objectives of the study were to determine differences in airway responsiveness to acetaldehyde between asthmatic and healthy subjects, and to examine the relationship between acetaldehyde responsiveness and the variability of peak expiratory flow (PEF).
Methods: The response to methacholine and acetaldehyde challenges was measured in 81 non-smoking adults (61 asthmatics and 20 normal controls). Subjects recorded PEF morning and evening for 14 days. The response to both bronchoconstrictor agents was measured by the PC20 (provocative concentration required to produce a 20% fall in FEV1). PEF variation was expressed as amplitude percentage mean, and as low percentage best (lowest PEF expressed as a percentage of the best PEF recorded).
Results: The two types of challenge yielded a similarly high level of sensitivity (100% for methacholine and 92% for acetaldehyde) and specificity (90 and 100%, respectively) to distinguish between asthma and controls. Asthmatic subjects were on average 265-fold less sensitive to acetaldehyde than to methacholine. PC20 acetaldehyde correlated weakly but significantly with both indices of PEF variation (amplitude percentage mean: rho = - 0.36, P = 0. 004; low percentage best: rho = 0.42, P = 0.001).
Conclusions: These results indicate that airway hyperresponsiveness to acetaldehyde is a sensitive and specific indicator for separating asthmatic and normal subjects. Airway responsiveness to methacholine or acetaldehyde and PEF variation are not reflecting the same pathophysiological process in the airways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2222.2000.00672.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Median effective dose of remimazolam combined with sufentanil for inhibiting laryngeal mask airway insertion responses in children of different ages.
Front Pharmacol
January 2025
Department of Anesthesiology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Introduction: We determined the median effective dose and 95% confidence interval (CI) of remimazolam required to inhibit laryngeal mask airway (LMA) insertion reactions combined with sufentanil 0.3 μg/kg in pediatric anesthesia.
Methods: Children scheduled to undergo elective laryngeal mask anesthesia were divided into the preschool (age: 3-6 years) and school-age (6-12 years) groups.
Advances in the awareness of tuberculosis-associated chronic obstructive pulmonary disease.
Chin Med J Pulm Crit Care Med
December 2024
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Center for Chronic Airway Diseases, Peking University Health Science Center, Peking University, Beijing 100191, China.
Tuberculosis (TB) significantly increases the risk of developing chronic obstructive pulmonary disease (COPD), positioning TB-associated COPD (TB-COPD) as a distinct category within the spectrum of respiratory diseases prevalent, especially in low- and middle-income countries. This condition results from the body's immune response to TB, leading to prolonged inflammation and consequent persistent lung damage. Diagnostic approaches, particularly post-bronchodilator spirometry, are vital for identifying airflow obstruction and confirming TB-COPD.
View Article and Find Full Text PDFAutonomic Reflexes With Epipharyngeal Abrasive Therapy (EAT).
Cureus
January 2025
Otolaryngology, Ito ENT Clinic, Funabashi, JPN.
A literature review was conducted of epipharyngeal abrasive therapy (EAT) in the treatment of chronic epipharyngitis, focusing on the mechanism of action by autonomic nerve stimulation. The mechanism of action of EAT in stimulating the immune system has recently become clear. However, the mechanism of action of EAT on the autonomic nervous system remains to be elucidated.
View Article and Find Full Text PDFA non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS.
Transl Lung Cancer Res
December 2024
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK.
Background: Anti-angiogenic agents, such as nintedanib and ramucirumab, when combined with docetaxel, are subsequent treatment options in patients with non-small cell lung cancer (NSCLC) who have failed on first-line chemotherapy or immunochemotherapy. However, to date, there are no validated predictive biomarkers for efficacy of anti-angiogenic therapies in this setting. The aim of this study was to explore whether genetic or genomic markers, alone or combined with clinical covariates, could be used to predict overall survival (OS) in patients with NSCLC who are eligible for treatment with nintedanib plus docetaxel.
View Article and Find Full Text PDFEstablishment of a mouse model of allergic asthma sensitized and triggered with PM2.5.
Int J Environ Health Res
January 2025
Department of Respiratory and Critical Care Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
To establish a mouse model of asthma sensitized and challenged with PM2.5 extract, 48 female BALB/c mice were included in this analysis. They were divided into six groups: normal control, ovalbumin (OVA) control, three PM2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!